Cargando…
FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
F-box and WD repeat domain-containing 7 (FBW7) has been characterized as a tumor suppressor, and its mutation or decreased expression has been observed in many types of human cancers. Our recent studies have uncovered that in pancreatic cancer, the KRAS mutation decreased FBW7 expression through pho...
Autores principales: | Hu, Qiangsheng, Qin, Yi, Zhang, Bo, Liang, Chen, Ji, Shunrong, Shi, Si, Xu, Wenyan, Xiang, Jinfeng, Liang, Dingkong, Ni, Quanxing, Yu, Xianjun, Xu, Jin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652962/ https://www.ncbi.nlm.nih.gov/pubmed/28765935 http://dx.doi.org/10.3892/or.2017.5856 |
Ejemplares similares
-
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer
por: Ji, Shunrong, et al.
Publicado: (2015) -
PRMT5 enhances tumorigenicity and glycolysis in pancreatic cancer via the FBW7/cMyc axis
por: Qin, Yi, et al.
Publicado: (2019) -
Complex roles of the stroma in the intrinsic resistance to gemcitabine in pancreatic cancer: where we are and where we are going
por: Liang, Chen, et al.
Publicado: (2017) -
TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer
por: Xiang, Jinfeng, et al.
Publicado: (2018) -
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis
por: Meng, Qingcai, et al.
Publicado: (2017)